IMMUNE-MEDIATED THYROIDITIS

This adverse event was reported 494 times

These drugs are most commonly taken by patients reporting IMMUNE-MEDIATED THYROIDITIS:

# Drug Count
0 NIVOLUMAB 183
1 IPILIMUMAB 131
2 CARBOPLATIN 88
3 PACLITAXEL 55
4 CYCLOPHOSPHAMIDE 28
5 CYCLOPHOSPHAMIDE FOR INJECTION 28
6 CYCLOPHOSPHAMIDE INJECTION, SOLUTION 28
7 DOXORUBICIN 20
8 DURVALUMAB 19
9 PANTOPRAZOLE 19
See all common drugs associated with IMMUNE-MEDIATED THYROIDITIS

IMMUNE-MEDIATED THYROIDITIS is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 IPILIMUMAB 131 0.0030
1 NIVOLUMAB AND RELATLIMAB-RMBW 1 0.0019
2 NIVOLUMAB 183 0.0019
3 EPIRUBICIN HYDROCHLORIDE 6 0.0009
4 TREMELIMUMAB 4 0.0009
5 DURVALUMAB 19 0.0009
6 ELRANATAMAB-BCMM 1 0.0009
7 IDECABTAGENE VICLEUCEL 1 0.0008
8 PIOGLITAZONE HYDROCHLORIDE 1 0.0008
9 CARBOPLATIN 88 0.0007
See all drugs enriched for association with IMMUNE-MEDIATED THYROIDITIS